Skip to main content
Clinical Trials/NCT02109016
NCT02109016
Terminated
Phase 2

A Single Arm, Open-label, Phase 2 Study to Assess the Efficacy and Safety of Lucitanib Given Orally as a Single Agent to Patients With Advanced/Metastatic Lung Cancer and FGF, VEGF, or PDGF Related Genetic Alterations

Clovis Oncology, Inc.19 sites in 5 countries18 target enrollmentApril 2014

Overview

Phase
Phase 2
Intervention
Lucitanib
Conditions
Non-Small Cell Lung Cancer
Sponsor
Clovis Oncology, Inc.
Enrollment
18
Locations
19
Primary Endpoint
Objective Response Rate (ORR)
Status
Terminated
Last Updated
6 years ago

Overview

Brief Summary

The purpose of this study is to determine whether lucitanib is safe and effective in the treatment of patients with advanced/metastatic lung cancer and fibroblast growth factor (FGF), vascular endothelial growth factor receptor (VEGF), or platelet derived growth factor (PDGF) related genetic alterations.

Detailed Description

Lucitanib is an oral inhibitor of the tyrosine kinase activity of FGFR 1-3, VEGFR 1-3, and PDGFR α/β. Lucitanib has demonstrated potent anti-tumor and anti-angiogenic activity in vitro proliferation assays and in vivo using human tumor xenograft models, with a trend for stronger efficacy in those with genomic aberrancies of FGF or PDGF. Abnormalities in the FGF, VEGF, and PDGF-related genes are observed across lung cancer histologies. The first in human trial of lucitanib demonstrated that daily lucitanib is clinically active in patients with advanced solid tumors. Specifically, patients with FGFR1-amplification appeared to derive particular benefit from lucitanib. Based on these results, this study is designed to explore the safety and anti-tumor activity of daily lucitanib in lung cancer patients with FGF, VEGF, and PDGF genetic alterations.

Registry
clinicaltrials.gov
Start Date
April 2014
End Date
September 2016
Last Updated
6 years ago
Study Type
Interventional
Study Design
Single Group
Sex
All

Investigators

Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Histologically or cytologically confirmed advanced/metastatic SCLC or NSCLC
  • Any of the following tumor tissue based genetic alterations: FGFR1, FGFR2, FGFR3, VEGFA, or PDGFRα amplification; Any FGFR1, FGFR2, or FGFR3 gene fusion; FGFR1, FGFR2, or FGFR3 activating mutation
  • Availability of tumor tissue sample suitable for the central confirmation of the genetic alteration and exploratory analyses
  • Eastern Cooperative Oncology Group (ECOG) of 0 or 1
  • Measurable disease per RECIST 1.1
  • Documented radiographic disease progression following at least one line of therapy in the advanced/metastatic setting

Exclusion Criteria

  • Tumors that are invading a major vessel; NSCLC tumors abutting to a major vessel
  • Uncontrolled hypertension, defined as SBP ≥ 140 mmHg and/or DBP ≥ 90 mmHg with optimized anti-hypertensive therapy
  • Uncontrolled hypothyroidism defined as serum thyroid stimulating hormone (TSH) higher than 5 mIU/mL while receiving appropriate thyroid hormone therapy
  • Symptomatic and/or untreated central nervous system metastases
  • Presence of another active cancer
  • Ongoing adverse events from surgery or prior anti-cancer therapies, including radiation, targeted, or cytotoxic therapies
  • Pregnant or breastfeeding women

Arms & Interventions

Lucitanib

Lucitanib given orally once daily on a continuous schedule. Starting dose is 10 mg/day.

Intervention: Lucitanib

Outcomes

Primary Outcomes

Objective Response Rate (ORR)

Time Frame: Screening, every 8 weeks; up to 2 years

Proportion of patients in whom a confirmed Complete Response (CR) or a confirmed Partial Response (PR), as best overall response according to RECIST criteria, is observed.

Secondary Outcomes

  • Progression-Free Survival (PFS)(Screening, every 8 weeks; up to 2 years)
  • Clinical Benefit Rate (CBR)(Screening, every 8 weeks; up to 2 years)
  • Tumor growth kinetics(Screening, every 8 weeks; up to 2 years)
  • Incidence of adverse events (AEs), clinical laboratory abnormalities, and dose modifications(Continuously; up to 2 years)
  • PK parameters of lucitanib(Cycle 1 Day 14 and 28, Cycle 2 Day 28, Cycle 3 Day 28)
  • Duration of response (DOR)(Screening, every 8 weeks; up to 2 years)
  • Duration of clinical benefit(Screening, every 8 weeks; up to 2 years)
  • Overall Survival (OS)(Continuously; up to 2 years)
  • Pharmacogenomic analysis of inter-patients variation in gene encoding ADME involved proteins(Cycle 1 Day 1)
  • Pharmacodynamic (PD) evaluation of lucitanib profile(Cycle 1 Day 1 and 14, End of Study)

Study Sites (19)

Loading locations...

Similar Trials